Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy

被引:6
|
作者
Lebret, Thierry [1 ]
Bouregba, Alain [1 ]
机构
[1] Hop Foch, Dept Urol, F-92151 Suresnes, France
关键词
prostate cancer; hormonal therapy; LHRH agonist; professional-patient relations; multidisciplinary care; nurse-led services;
D O I
10.1111/j.1464-410X.2008.07785.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To establish the roles of the urologist, general practitioner (GP) and nurse from the perspective of the patient with prostate cancer receiving hormone therapy, and to assess patient satisfaction, in particular with management and information needs. PATIENTS AND METHODS Patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue (LHRH-a) therapy were recruited by a representative sample of 58 French urologists (March to April 2007) and invited to complete a 42-item questionnaire. RESULTS In all, 350 representative patients participated in the study; > 90% were totally or quite satisfied with the information given by their urologist at diagnosis and the start of treatment. Their main contact during treatment was with the nurse who gave the injection (84% of patients). The nurse's main role was to provide clarity (60% of patients), guidance (35%) and support to the family (28%). Fewer patients discussed disease stage and progression with their nurse (29%) than with a doctor (urologist, 63%; or GP, 61%). Fewer also discussed treatment (24% vs 32%) but as many patients discussed the impact of their disease and treatment with their nurse as with their doctor (e.g. 33% discussed general health and fatigue with the nurse, vs 26% with the urologist). The need for contact with a health professional was greater during the early stages of treatment. Patients treated for < 12 months with 3-monthly injections were less likely to be in favour of spacing injections than patients treated for >= 3 years. CONCLUSION The patient consults the urologist for reliable information on disease and treatment, and to the GP for further support, if needed, but the nurse has the pivotal role. A 3-monthly injection schedule enables regular face-to-face contact between the nurse and the patient and their family, and contributes towards the patient's coping strategies and quality of life.
引用
收藏
页码:1419 / 1424
页数:6
相关论文
共 50 条
  • [31] ANAMEM: PROSPECTIVE AND OBSERVATIONAL STUDY TO EVALUATE COGNITIVE CHANGES IN PROSTATE CANCER PATIENTS UNDERGOING LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUE TREATMENT
    Morote, Juan
    Tabernero, Angel
    Luis Alvarez-Ossorio, Jose
    Pablo Ciria, Juan
    Luis Dominguez-Escrig, Jose
    Vazquez, Fernando
    Angulo, Javier C.
    Javier Lopez, Francisco
    De la Iglesia, Ramon
    Romero, Jesus
    JOURNAL OF UROLOGY, 2015, 193 (04): : E929 - E929
  • [32] Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological cancer therapy
    Gründker, C
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 (05) : 569 - 572
  • [33] LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONIST REDUCE SERUM ADRENAL ANDROGEN LEVELS IN PROSTATE CANCER PATIENTS
    Miyazawa, Yoshiyuki
    Kato, Haruo
    Furuya, Yosuke
    Nitta, Takashi
    Sekine, Yoshitaka
    Koike, Hidekazu
    Matsui, Hiroshi
    Shibata, Yasuhiro
    Ito, Kazuto
    Suzuki, Kazuhiro
    JOURNAL OF UROLOGY, 2016, 195 (04): : E675 - E676
  • [34] Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists
    Matveev, V. B.
    Alekseev, B. Ya
    Kamolov, B. Sh
    Markova, A. S.
    ONKOUROLOGIYA, 2021, 17 (02): : 83 - 92
  • [35] Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist
    Noguchi, M
    Noda, S
    Yoshida, M
    Ueda, S
    Shiraishi, T
    Itoh, K
    INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (02) : 103 - 109
  • [36] Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
    Garnick, Marc B.
    Hafron, Jason
    Crawford, E. David
    JOURNAL OF UROLOGY, 2024, 211 (03):
  • [37] Effect of Luteinizing Hormone-Releasing Hormone Analogue on the Sexual Behavior of Sacalia quadriocellata
    HE Bin
    LIU Yuxiang
    SHI Haitao
    FU Lirong
    WANG Jichao
    Asian Herpetological Research, 2010, 1 (01) : 40 - 43
  • [38] IMPACT OF LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) THERAPY ON QUALITY OF LIFE IN MEN WITH PROSTATE CANCER: A CONTROLLED COMPARISON
    Hussin, Mallory
    Wise, Edward
    Hicks, Charissa
    Phillips, Kristin
    Rivers, Brian
    Jim, Heather
    Jacobsen, Paul
    ANNALS OF BEHAVIORAL MEDICINE, 2011, 41 : S87 - S87
  • [39] Effect of Luteinizing Hormone-Releasing Hormone Analogue on the Sexual Behavior of Sacalia quadriocellata
    He Bin
    Liu Yuxiang
    Shi Haitao
    Fu Lirong
    Wang Jichao
    ASIAN HERPETOLOGICAL RESEARCH, 2010, 1 (01) : 40 - 43
  • [40] Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: Implications in the management of prostate cancer
    Chang, SS
    UROLOGY, 2003, 62 (6A) : 29 - 35